Evidence map›Paper›PMID 32753692›Full record

ArticleScientific reports2020

A lncRNA landscape in breast cancer reveals a potential role for AC009283.1 in proliferation and apoptosis in HER2-enriched subtype.

Alberto Cedro-Tanda, Magdalena Ríos-Romero, Sandra Romero-Córdoba, Mireya Cisneros-Villanueva, Rosa Gloria Rebollar-Vega, Luis Alberto Alfaro-Ruiz, Silvia Jiménez-Morales, Carlos Domínguez-Reyes, Felipe Villegas-Carlos, Alberto Tenorio-Torres and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Alberto Cedro-TandaLaboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.ORCID http://orcid.org/0000-0001-8708-462X
Magdalena Ríos-RomeroLaboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.
Sandra Romero-CórdobaLaboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.ORCID http://orcid.org/0000-0002-5591-696X
Mireya Cisneros-VillanuevaLaboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.
Rosa Gloria Rebollar-VegaGenomics Laboratory, Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Luis Alberto Alfaro-RuizLaboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.
Silvia Jiménez-MoralesLaboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.
Carlos Domínguez-ReyesFUCAM, Instituto de Enfermedades de la Mama, Mexico City, Mexico.
Felipe Villegas-CarlosFUCAM, Instituto de Enfermedades de la Mama, Mexico City, Mexico.
Alberto Tenorio-TorresFUCAM, Instituto de Enfermedades de la Mama, Mexico City, Mexico.
Veronica Bautista-PiñaFUCAM, Instituto de Enfermedades de la Mama, Mexico City, Mexico.
Fredy Omar Beltrán-AnayaLaboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.ORCID http://orcid.org/0000-0001-6862-7879
Alfredo Hidalgo-MirandaLaboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico. ahidalgo@inmegen.gob.mx.ORCID http://orcid.org/0000-0003-2315-3977
National Institute of Genomic Medicine · MXInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXUniversidad Autónoma de la Ciudad de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most commonly diagnosed neoplasm in women worldwide with a well-recognized heterogeneous pathology, classified into four molecular subtypes: Luminal A, Luminal B, HER2-enriched and Basal-like, each one with different biological and clinical characteristics. Long non-coding RNAs (lncRNAs) represent 33% of the human transcriptome and play critical roles in breast carcinogenesis, but most of their functions are still unknown. Therefore, cancer research could benefit from continued exploration into the biology of lncRNAs in this neoplasm. We characterized lncRNA expression portraits in 74 breast tumors belonging to the four molecular subtypes using transcriptome microarrays. To infer the biological role of the deregulated lncRNAs in the molecular subtypes, we performed co-expression analysis of lncRNA-mRNA and gene ontology analysis. We identified 307 deregulated lncRNAs in tumor compared to normal tissue and 354 deregulated lncRNAs among the different molecular subtypes. Through co-expression analysis between lncRNAs and protein-coding genes, along with gene enrichment analysis, we inferred the potential function of the most deregulated lncRNAs in each molecular subtype, and independently validated our results taking advantage of TCGA data. Overexpression of the AC009283.1 was observed in the HER2-enriched subtype and it is localized in an amplification zone at chromosome 17q12, suggesting it to be a potential tumorigenic lncRNA. The functional role of lncRNA AC009283.1 was examined through loss of function assays in vitro and determining its impact on global gene expression. These studies revealed that AC009283.1 regulates genes involved in proliferation, cell cycle and apoptosis in a HER2 cellular model. We further confirmed these findings through ssGSEA and CEMITool analysis in an independent HER2-amplified breast cancer cohort. Our findings suggest a wide range of biological functions for lncRNAs in each breast cancer molecular subtype and provide a basis for their biological and functional study, as was conducted for AC009283.1, showing it to be a potential regulator of proliferation and apoptosis in the HER2-enriched subtype.

Indexed as

ApoptosisCell ProliferationChromosomes, Human, Pair 17Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansMCF-7 CellsRNA, Long NoncodingERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesRNA, Long Noncoding

Identifiers

PMID32753692
PMCPMC7403317
OpenAlexW3047238677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.